Kuhnil Pharma to export dyslipidemia treatment to Mexico

Kuhnil Pharmaceutical said it signed a license and export contract for Rosumega, its dyslipidemia treatment, with Siegfried Rhein, a Mexican pharmaceutical company.

Under the accord, Kuhnil will export Rosumega finished products to Mexico through Siegfried Line.

Siegfried plans to start the licensing process in Mexico early next year, and strengthen its cardiovascular product portfolio through the successful launch of Rosumega.

"The company expects that this contract will serve as an opportunity for Rosumega, which has obtained approval for finished products in the European market, to expand its export regions not only in Europe but also in Latin America," a Kuhnil official said. "We also believe that this deal will have a positive impact on the global expansion of Atomega, a similar combination treatment for dyslipidemia developed by the company."

Rosumega Soft Capsule is a combination treatment developed by Kuhnil and currently marketed in the European market and Mongolia. It is a product produced with the world's first soft capsule multi-coating patent registered in Korea, the U.S., Australia, China, Japan, Canada, Russia, and Europe.

Siegfried was established in 1974 as the Mexican branch of Roemmers Group, the largest pharmaceutical group in Argentina by sales.

According to Kuhnil, Siegfried is evaluated as a leading pharmaceutical company in Mexico based on its products in various therapeutic areas and strong local sales.